- Our Company
- News & Events
- Contact Us
Check out this press release on how Guardant360® test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients, according to the researchers at Samsung Medical Center in Seoul, Korea.
Visit us online @ guardanthealthamea.com to find out more about Guardant360®, the global leader in liquid biopsy. If you have any queries, send us an email at email@example.com or contact us on WhatsApp: +65 8940 0360.
Guardant360®. Test. Take Action.